ReviewFuture cardiology2025
Current appraisal of venous excess ultrasound (VExUS) and its applications in the treatment of cardiovascular disease.
Review in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Venous excess doppler ultrasound: What radiologists should know in 2026.World journal of radiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bedside assessment of venous congestion is key to managing hospitalized adults with cardiovascular disease and guiding fluid management to achieve euvolemia. Current methods include physical examination, radiographic imaging, and point-of-care ultrasound (POCUS) of the inferior vena cava (IVC). While accessible, physical exam and IVC measurements are prone to errors and variability. Right heart catheterization (RHC), considered the gold standard, is invasive, costly, and often unavailable. A novel ultrasound technique, Venous Excess Ultrasound (VExUS), offers a noninvasive alternative for assessing venous congestion by characterizing the IVC and hepatic, portal, and intrarenal veins. Rapidly evolving literature on VExUS has created controversy and uncertainty around its application to patients with cardiovascular disease. This review summarizes the utility of the VExUS scoring system as a bedside tool for assessing venous congestion in adults with cardiovascular disease. It will discuss the methodology of VExUS, its performance compared to traditional IVC measurements and RHC, and its applications in various cardiovascular conditions including acute decompensated heart failure (ADHF), acute coronary syndromes (ACS), tricuspid regurgitation (TR), cardiorenal syndromes (CRS), cardiogenic shock (CS), and patients undergoing cardiac surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.